Search: (WFRF:(Chavez Alejandro)) >
FLT3–ITD and its cu...
-
Lagunas-Rangel, Francisco AlejandroGraduate Studies Division, Faculty of Biological and Medical Sciences “Dr Ignacio Chávez”, Universidad Michoacana de San Nicolás de Hidalgo, Av. Rafael Carrillo W/N, corner with Dr. Salvador González Herrejón, Bosque Cuauhtémoc, 58020, Morelia, Michoacán, Mexico
(author)
FLT3–ITD and its current role in acute myeloid leukaemia
- Article/chapterEnglish2017
Publisher, publication year, extent ...
-
2017-05-03
-
Springer Nature,2017
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-444522
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-444522URI
-
https://doi.org/10.1007/s12032-017-0970-xDOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:for swepub-publicationtype
Notes
-
FMS-like tyrosine kinase 3 (FLT3) is a proto-oncogene involved in crucial steps of haematopoiesis such as proliferation, differentiation and survival. In recent years, FLT3 has been an important marker in different haematological malignancies, highlighting in acute myeloid leukaemia, where FLT3 mutations have been associated with the clinical prognosis, treatment and survival of patients. The most common form of FLT3 mutation is an internal tandem duplication (ITD) that promotes ligand-independent auto-phosphorylation and constitutive activation of the receptor. FLT3–ITD has been strongly associated with a bad prognosis, leukocytosis, high blast counts, increased risk of relapse and shorter overall survival. In order to improve the clinical condition of FLT3–ITD-positive patients, several FLT3 inhibitors have been developed showing variable results. Currently, the main challenges to be overcome are the different forms of resistance to FLT3 inhibitors. Thus, the purpose of this review is to present, in a general way, the current role that FLT3–ITD mutation plays in patients with AML, with a particular emphasis on the molecular mechanisms associated with clinical prognosis, treatment, and survival of patients.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Chávez-Valencia, VeniceGraduate Studies Division, Faculty of Biological and Medical Sciences “Dr Ignacio Chávez”, Universidad Michoacana de San Nicolás de Hidalgo, Av. Rafael Carrillo W/N, corner with Dr. Salvador González Herrejón, Bosque Cuauhtémoc, 58020, Morelia, Michoacán, Mexico; Nephrology Department, Hospital General Regional No.1, Instituto Mexicano del Seguro Social, Av. Bosques de los Olivos No. 101, Comunidad La Goleta, 61301, Morelia, Michoacán, Mexico
(author)
-
Graduate Studies Division, Faculty of Biological and Medical Sciences “Dr Ignacio Chávez”, Universidad Michoacana de San Nicolás de Hidalgo, Av. Rafael Carrillo W/N, corner with Dr. Salvador González Herrejón, Bosque Cuauhtémoc, 58020, Morelia, Michoacán, MexicoGraduate Studies Division, Faculty of Biological and Medical Sciences “Dr Ignacio Chávez”, Universidad Michoacana de San Nicolás de Hidalgo, Av. Rafael Carrillo W/N, corner with Dr. Salvador González Herrejón, Bosque Cuauhtémoc, 58020, Morelia, Michoacán, Mexico; Nephrology Department, Hospital General Regional No.1, Instituto Mexicano del Seguro Social, Av. Bosques de los Olivos No. 101, Comunidad La Goleta, 61301, Morelia, Michoacán, Mexico
(creator_code:org_t)
Related titles
-
In:Medical Oncology: Springer Nature34:61357-05601559-131X
Internet link
Find in a library
To the university's database